Hyperthermia in Cancer Therapy — CPB 0278 | AETNA Coverage Update

TL;DR: Aetna, a CVS Health company, modified CPB 0278 governing hyperthermia in cancer therapy, effective October 17, 2025. Billing teams need to map covered indications to the right CPT and HCPCS codes — or face claim denial on a procedure set with significant reimbursement exposure.

This update to the Aetna hyperthermia coverage policy touches CPT codes 77600, 96547, and 96548 on the covered side, and flags CPT 77605, 77610, 77615, 77620, and 96440 as not covered for the indications listed in CPB 0278. If your practice bills for HIPEC, regional hyperthermic melphalan perfusion, or superficial external hyperthermia, you need to read this before billing an Aetna claim under these codes.

---

Quick-Reference Table

Field	Detail Copy
Payer	Aetna, a CVS Health company
Policy	Hyperthermia in Cancer Therapy
Policy Code	CPB 0278
Change Type	Modified
Effective Date	October 17, 2025
Impact Level	High
Specialties Affected	Surgical oncology, gynecologic oncology, medical oncology, radiation oncology, dermatology/oncology
Key Action	Audit charge capture for CPT 96547, 96548, and 77600 to confirm diagnoses map to covered indications before billing Aetna

---

Aetna Hyperthermia Cancer Therapy Coverage Criteria and Medical Necessity Requirements 2025

Aetna's CPB 0278 hyperthermia coverage policy draws a sharp line between what's covered and what's experimental. Six specific indications clear the medical necessity bar. Everything else does not.

Here's what Aetna considers medically necessary:

1. Cytoreductive surgery plus HIPEC for mucinous carcinoma peritonei (MCP). This covers all three MCP subtypes: low-grade (MCP-L, formerly called diffuse peritoneal adenomatosis or DPAM), high-grade (MCP-H, formerly called peritoneal mucinous carcinoma or PMCA), and high-grade with signet ring cells (MCP-H-S, formerly called PMCA-S). The older terminology is important — your coders may still see these legacy labels in operative and pathology reports.

2. Cytoreductive surgery plus HIPEC for peritoneal mesothelioma. This is distinct from pleural mesothelioma. Pleural HIPEC is explicitly not covered under this policy. If you see a mesothelioma case, confirm the site before billing CPT 96547.

3. Cytoreductive surgery plus HIPEC for goblet cell carcinoid tumor. This is a rare appendiceal malignancy. Coverage is specific to this histology — appendiceal carcinoma without mucinous carcinoma peritonei does not qualify.

4. HIPEC with cisplatin (HCPCS J9060) at interval debulking surgery for FIGO stage III ovarian cancer. Two conditions must align: the correct disease stage and the specific drug. Using melphalan instead of cisplatin, or billing for a different surgical timing, puts this claim at risk.

5. Regional hyperthermic melphalan perfusion for stage II, IIIA, and stage III in-transit extremity melanoma. Stage matters here. Stage I, IIIB, and IIIAB are not covered. Regional hyperthermic perfusion with any chemotherapy other than melphalan is also not covered.

6. Sequential radiation plus local/regional external hyperthermia (CPT 77600) for superficial malignancies. This covers primary or metastatic cutaneous or subcutaneous tumors — examples include superficial recurrent melanoma, chest wall recurrence of breast cancer, and cervical lymph node metastases from head and neck cancer. The key word is "sequential" — the policy specifies radiation combined with hyperthermia, not hyperthermia alone.

Medical necessity documentation needs to align with these specific criteria. Vague operative notes referencing "peritoneal malignancy" without confirming the histology and subtype will not support these claims. Make sure your clinical documentation team knows what Aetna needs to see.

Prior authorization requirements for these procedures are not explicitly detailed in CPB 0278 itself, but high-cost surgical oncology procedures — especially HIPEC combined with cytoreductive surgery — almost always require prior auth under Aetna commercial plans. Confirm prior authorization requirements with Aetna directly for each patient's specific plan before scheduling.

---

Aetna Hyperthermia Exclusions and Non-Covered Indications

The exclusion list in CPB 0278 is long. That's intentional — Aetna is drawing explicit boundaries around a procedure category that clinicians continue to explore in new tumor types.

Ten broad categories land in experimental, investigational, or unproven status:

Deep hyperthermia (CPT 77605) is not covered alone or with radiation therapy, for any indication.

HIPEC for 17 specific diagnoses is not covered. That list includes colon cancer, gastric cancer, pancreatic cancer, bladder cancer, hepatocellular carcinoma, and others. Colorectal signet ring carcinoma is separately excluded — which matters because some coders might conflate it with the covered MCP-H-S subtype. They are not the same.

Intrapleural HIPEC and pleural HIPEC are not covered — for pleural mesothelioma, metastatic pleural malignancies, or any other indication. This is a critical distinction from the covered peritoneal mesothelioma indication.

Interstitial, intracavitary, and intraluminal hyperthermia — CPT codes 77610, 77615, and 77620 — are not covered for the indications listed in this policy.

Prophylactic HIPEC for gastric cancer is not covered, even as a prevention strategy in high-risk patients.

Regional hyperthermic melphalan perfusion for stage I, IIIB, and IIIAB melanoma is not covered. And any regional hyperthermic perfusion paired with a chemotherapy agent other than melphalan is not covered — regardless of stage.

Regional hyperthermic perfusion for non-extremity indications — including non-small cell lung cancer — is not covered.

Superficial hyperthermia for paranasal sinus and nasal cavity cancer is not covered. This is a narrow carve-out from the otherwise covered superficial hyperthermia indication.

Transrectal ultrasound hyperthermia for prostate cancer is not covered.

Whole body hyperthermia is not covered for testicular cancer or any other indication.

The real issue here is the HIPEC exclusion list. Several diagnoses on it — colon cancer, gastric cancer, pancreatic cancer — are tumor types where HIPEC is actively used in academic centers. Aetna is explicitly not following clinical adoption on these. If your oncology program performs HIPEC for colorectal peritoneal carcinomatosis, expect claim denial on Aetna patients unless the diagnosis maps to a covered MCP subtype or peritoneal mesothelioma.

---

Coverage Indications at a Glance

---

Aetna Hyperthermia Billing Guidelines and Action Items 2025

Here's what your billing team should do before October 17, 2025:

Copy Action Items

If your practice handles significant volume of peritoneal surface malignancy cases or appendiceal tumors, the stakes here are high. Talk to your compliance officer before the October 17, 2025 effective date to review how CPB 0278 applies to your specific patient mix and documentation protocols.

---

CPT, HCPCS, and ICD-10 Codes for Hyperthermia in Cancer Therapy Under CPB 0278

Covered CPT Codes (When Selection Criteria Are Met)

Code	Type	Description Copy
77600	CPT	Hyperthermia, externally generated; superficial (heating to a depth of 4 cm or less)
96547	CPT	Intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) procedure, including separate incision
96548	CPT	Each additional 30 minutes (list separately in addition to code for primary procedure) — note: not covered for all indications; confirm against covered list

Not Covered CPT Codes

HCPCS Codes

Code	Type	Description Copy
J8600	HCPCS	Melphalan, oral, 2 mg
J9060	HCPCS	Injection, cisplatin, powder or solution, 10 mg
J9245	HCPCS	Injection, melphalan HCl, 50 mg

Key ICD-10-CM Diagnosis Codes

The full ICD-10 code set in CPB 0278 spans 373 codes. The table below captures the primary diagnosis categories referenced in coverage and exclusion criteria. Review the full code list at app.payerpolicy.org/p/aetna/0278 before billing.

---